Lymphangioleiomyomatosis: a clinical update
- PMID: 18252917
- DOI: 10.1378/chest.07-0898
Lymphangioleiomyomatosis: a clinical update
Abstract
Lymphangioleiomyomatosis (LAM) is a rare, cystic lung disease that is associated with mutations in tuberous sclerosis genes, renal angiomyolipomas, lymphatic spread, and remarkable female gender restriction. The clinical course of LAM is characterized by progressive dyspnea on exertion, recurrent pneumothorax, and chylous fluid collections. Lung function declines at approximately twofold to threefold times the rate of healthy subjects, based on an annual drop in FEV1 of 75 to 120 mL in reported series. The diagnosis of pulmonary LAM can be made on high-resolution CT (HRCT) scan with reasonable certainty by expert radiologists, but generally requires a lung biopsy in cases in which tuberous sclerosis complex, angiomyolipomata, or chylous effusions are absent. The currently available treatment strategies are based on the antagonism of estrogen action, and are empiric and unproven. A trial of bronchodilators is warranted in patients with reversible airflow obstruction seen on pulmonary function testing. Pleurodesis should be performed with the initial pneumothorax, because the rate of recurrence is high. Angiomyolipomas that exceed 4 cm in size are more likely to bleed and should be evaluated for embolization. Air travel is well-tolerated by most patients with LAM. Lung transplantation is an important option for LAM patients, and can be safely performed by experienced surgeons despite prior unilateral or bilateral pleurodesis in most patients. Women with unexplained recurrent pneumothorax, tuberous sclerosis, or a diagnosis of primary spontaneous pneumothorax or emphysema in the setting of limited or absent tobacco use should undergo HRCT scan screening for LAM. Multicenter clinical trials based on several well-defined molecular targets are currently underway in the United States and Europe.
Comment in
-
Variability in the prevalence of acute bronchoresponsiveness in different populations of patients with lymphangioleiomyomatosis.Chest. 2008 Jul;134(1):217; author reply 218. doi: 10.1378/chest.08-0454. Chest. 2008. PMID: 18628234 No abstract available.
Similar articles
-
Clinical and histopathological alterations of lymphangioleiomyomatosis in 14 Chinese patients.Chin Med J (Engl). 2009 Aug 20;122(16):1895-900. Chin Med J (Engl). 2009. PMID: 19781367
-
Lymphangioleiomyomatosis: new concepts in pathogenesis, diagnosis, and treatment.Semin Respir Crit Care Med. 2012 Oct;33(5):486-97. doi: 10.1055/s-0032-1325159. Epub 2012 Sep 21. Semin Respir Crit Care Med. 2012. PMID: 23001803 Review.
-
Changes in lung function and chylous effusions in patients with lymphangioleiomyomatosis treated with sirolimus.Ann Intern Med. 2011 Jun 21;154(12):797-805, W-292-3. doi: 10.7326/0003-4819-154-12-201106210-00007. Ann Intern Med. 2011. PMID: 21690594 Free PMC article.
-
Pulmonary lymphangioleiomyomatosis. A study of 69 patients. Groupe d'Etudes et de Recherche sur les Maladies "Orphelines" Pulmonaires (GERM"O"P).Medicine (Baltimore). 1999 Sep;78(5):321-37. doi: 10.1097/00005792-199909000-00004. Medicine (Baltimore). 1999. PMID: 10499073
-
Lymphangioleiomyomatosis.Eur Respir J. 2006 May;27(5):1056-65. doi: 10.1183/09031936.06.00113303. Eur Respir J. 2006. PMID: 16707400 Review.
Cited by
-
Lymphangioleiomyomatosis and pregnancy: a mini-review.Arch Gynecol Obstet. 2024 Jun;309(6):2339-2346. doi: 10.1007/s00404-024-07478-2. Epub 2024 Apr 9. Arch Gynecol Obstet. 2024. PMID: 38594407 Free PMC article. Review.
-
The Evolving Landscape of Therapeutics for Epilepsy in Tuberous Sclerosis Complex.Biomedicines. 2023 Dec 7;11(12):3241. doi: 10.3390/biomedicines11123241. Biomedicines. 2023. PMID: 38137462 Free PMC article. Review.
-
Lymphangioleiomyomatosis with Tuberous Sclerosis Complex-A Case Study.J Pers Med. 2023 Nov 12;13(11):1598. doi: 10.3390/jpm13111598. J Pers Med. 2023. PMID: 38003913 Free PMC article.
-
Case report: Pulmonary synovial sarcoma in a long-term survivor of childhood Hodgkin lymphoma.Front Oncol. 2023 Feb 24;13:1096160. doi: 10.3389/fonc.2023.1096160. eCollection 2023. Front Oncol. 2023. PMID: 36910640 Free PMC article.
-
Statins block mammalian target of rapamycin pathway: a possible novel therapeutic strategy for inflammatory, malignant and neurodegenerative diseases.Inflammopharmacology. 2023 Feb;31(1):57-75. doi: 10.1007/s10787-022-01077-w. Epub 2022 Dec 27. Inflammopharmacology. 2023. PMID: 36574095 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous